Interferon regulatory factor 3 plays an anti-inflammatory role in microglia by activating the PI3K/Akt pathway

Journal of Neuroinflammation

Sunhee C Lee¹  Hyeon-Sook Suh¹  Leonid Tarassishin¹ 

[1] Departments of Pathology (Neuropathology), Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx NY, USA

关键词: TLR;    interferon-beta;    microarray;    antiviral genes;    chemokines;    cytokines;    human;    innate immunity;    neurodegeneration;    neuroinflammation;   

Others  :  1212910
DOI  :  10.1186/1742-2094-8-187

 received in 2011-07-15, accepted in 2011-12-30,  发布年份 2011

【 摘 要 】

Background

Microglia are the principal cells involved in the innate immune response in the CNS. Activated microglia produce a number of proinflammatory cytokines implicated in neurotoxicity but they also are a major source of anti-inflammatory cytokines, antiviral proteins and growth factors. Therefore, an immune therapy aiming at suppressing the proinflammatory phenotype while enhancing the anti-inflammatory, growth promoting phenotype would be of great benefit. In the current study, we tested the hypothesis that interferon regulatory factor 3 (IRF3), a transcription factor required for the induction of IFNβ following TLR3 or TLR4 activation, is critical to the microglial phenotype change from proinflammatory to anti-inflammatory, and that this phenotype change can be greatly facilitated by IRF3 gene transfer.

Methods

Cultures of primary human fetal microglia were transduced with IRF3 using recombinant adenovirus (Ad-IRF3) and subjected to microarray analysis, real-time PCR, immunoblotting and ELISA to determine inflammatory gene expression. Two different types of immune stimuli were tested, the TLR ligands, poly IC (PIC) and LPS, and the proinflammatory cytokines, IL-1/IFNγ. In addition, the role of the PI3K/Akt pathway was examined by use of a pharmacological inhibitor, LY294002.

Results

Our results show that Ad-IRF3 suppressed proinflammatory genes (IL-1α, IL-1β, TNFα, IL-6, IL-8 and CXCL1) and enhanced anti-inflammatory genes (IL-1 receptor antagonist, IL-10 and IFNβ) in microglia, regardless of the cell stimuli applied. Furthermore, Ad-IRF3 activated Akt, and LY294002 reversed the effects of Ad-IRF3 on microglial inflammatory gene expression. pAkt was critical in LPS- or PIC-induced production of IL-10 and IL-1ra. Significantly, microglial IFNβ protein production was also dependent on pAkt and required both Ad-IRF3 and immunological stimuli (PIC > IL-1/IFNγ). pAkt played much less prominent and variable roles in microglial proinflammatory gene expression. This anti-inflammatory promoting role of PI3K/Akt appeared to be specific to microglia, since astrocyte proinflammatory gene expression (as well as IFNβ expression) required PI3K/Akt.

Conclusions

Our results show a novel anti-inflammatory role for the PI3K/Akt signaling pathway in microglia. They further suggest that IRF3 gene therapy could facilitate the microglial phenotype switch from proinflammatory ("M1-like") to anti-inflammatory and immunomodulatory ("M2-like"), in part, by augmenting the level of pAkt.

【 授权许可】

   
2011 Tarassishin et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

【 参考文献 】

• [1]Kawai T, Akira S: Antiviral signaling through pattern recognition receptors. J Biochem 2007, 141:137-145.
• [2]Carpentier PA, Duncan DS, Miller SD: Glial toll-like receptor signaling in central nervous system infection and autoimmunity. Brain Behav Immun 2008, 22:140-147.
• [3]Hiscott J, Lin R, Nakhaei P, Paz S: MasterCARD: a priceless link to innate immunity. Trends Mol Med 2006, 12:53-56.
• [4]Lee SC, Cosenza MA, Si Q, Rivieccio M, Brosnan CF: The CNS: CELLS, TISSUES AND REACTIONS TO INSULT CYTOKINES AND THE CNS. Edited by Ransohoff RM, Benveniste EN. Boca Raton, FL, CRC Press; 2005:1-22.
• [5]Suh HS, Brosnan CF, Lee SC: Toll-like receptors in CNS viral infections. Curr Top Microbiol Immunol 2009, 336:63-81.
• [6]Hanisch UK, Kettenmann H: Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007, 10:1387-1394.
• [7]Perry VH, Nicoll JA, Holmes C: Microglia in neurodegenerative disease. Nat Rev Neurol 2010, 6:193-201.
• [8]Lee SC: Microglia and innate immunity in neuroAIDS The neurology of AIDS. Edited by Gendelman HE. Oxford University Press; 2011.
• [9]Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996, 19:312-318.
• [10]Perry VH, Gordon S: Macrophages and microglia in the nervous system. Trends Neurosci 1988, 11:273-277.
• [11]Streit WJ, Conde JR, Fendrick SE, Flanary BE, Mariani CL: Role of microglia in the central nervous system's immune response. Neurol Res 2005, 27:685-691.
• [12]Gordon S: Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
• [13]Schwartz M, Butovsky O, Bruck W, Hanisch UK: Microglial phenotype: is the commitment reversible? Trends Neurosci 2006, 29:68-74.
• [14]Suh HS, Zhao ML, Rivieccio M, Choi S, Connolly E, Zhao Y, Takikawa O, Brosnan CF, Lee SC: Astrocyte indoleamine 2, 3 dioxygenase (IDO) is induced by the TLR3 ligand poly IC: mechanism of induction and role in anti-viral response. J Virol 2007, 81:9838-9850.
• [15]Peltier DC, Simms A, Farmer JR, Miller DJ: Human neuronal cells possess functional cytoplasmic and TLR-mediated innate immune pathways influenced by phosphatidylinositol-3 kinase signaling. J Immunol 2010, 184:7010-7021.
• [16]Lin R, Heylbroeck C, Pitha PM, Hiscott J: Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol Cell Biol 1998, 18:2986-2996.
• [17]Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J: Triggering the interferon antiviral response through an IKK-related pathway. Science 2003, 300:1148-1151.
• [18]Grandvaux N, Servant MJ, tenOever B, Sen GC, Balachandran S, Barber GN, Lin R, Hiscott J: Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J Virol 2002, 76:5532-5539.
• [19]Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T: IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003, 4:491-496.
• [20]Doyle S, Vaidya S, O'Connell R, Dadgostar H, Dempsey P, Wu T, Rao G, Sun R, Haberland M, Modlin R, Cheng G: IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 2002, 17:251-263.
• [21]Suh HS, Zhao ML, Choi N, Belbin TJ, Brosnan CF, Lee SC: TLR3 and TLR4 are innate antiviral immune receptors in human microglia: role of IRF3 in modulating antiviral and inflammatory response in the CNS. Virology 2009, 392:246-259.
• [22]Marsh B, Stevens SL, Packard AE, Gopalan B, Hunter B, Leung PY, Harrington CA, Stenzel-Poore MP: Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3. J Neurosci 2009, 29:9839-9849.
• [23]Tokunaga T, Naruke Y, Shigematsu S, Kohno T, Yasui K, Ma Y, Chua KJ, Katayama I, Nakamura T, Hishikawa Y, Koji T, Yatabe Y, Nagayasu T, Fujita T, Matsuyama T, Hayashi H: Aberrant expression of interferon regulatory factor 3 in human lung cancer. Biochem Biophys Res Commun 2010, 397:202-207.
• [24]Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J: The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 2010, 11:1005-1013.
• [25]Okumura A, Alce T, Lubyova B, Ezelle H, Strebel K, Pitha PM: HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology 2008, 373:85-97.
• [26]Lee SC, Liu W, Brosnan CF, Dickson DW: Characterization of human fetal dissociated CNS cultures with an emphasis on microglia. Lab Invest 1992, 67:465-475.
• [27]Rivieccio MA, Suh HS, Zhao Y, Zhao ML, Chin KC, Lee SC, Brosnan CF: TLR3 ligation activates an antiviral response in human fetal astrocytes: a role for viperin/cig5. J Immunol 2006, 177:4735-4741.
• [28]Rivieccio MA, John GR, Song X, Suh HS, Zhao Y, Lee SC, Brosnan CF: The cytokine IL-1beta activates IFN response factor 3 in human fetal astrocytes in culture. J Immunol 2005, 174:3719-3726.
• [29]Tarassishin L, Loudig O, Bauman A, Shafit-Zagardo B, Suh HS, Lee SC: Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155*. Glia 2011, 59:1911-1922.
• [30]Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I: IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol 2007, 179:3434-3442.
• [31]Uze G, Monneron D: IL-28 and IL-29: newcomers to the interferon family. Biochimie 2007, 89:729-734.
• [32]Levy DE, Marie I, Smith E, Prakash A: Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. J Interferon Cytokine Res 2002, 22:87-93.
• [33]Severa M, Remoli ME, Giacomini E, Annibali V, Gafa V, Lande R, Tomai M, Salvetti M, Coccia EM: Sensitization to TLR7 agonist in IFN-beta-preactivated dendritic cells. J Immunol 2007, 178:6208-6216.
• [34]Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, Yoshimoto T: Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol 2010, 2010::.
• [35]Genin P, Algarte M, Roof P, Lin R, Hiscott J: Regulation of RANTES chemokine gene expression requires cooperation between NF-kB and IFN-regulatory factor transcription factors. J Immunol 2000, 164:5352-5361.
• [36]Joung SM, Park ZY, Rani S, Takeuchi O, Akira S, Lee JY: Akt contributes to activation of the TRIF-dependent signaling pathways of TLRs by interacting with TANK-binding kinase 1. J Immunol 2011, 186:499-507.
• [37]Liu J, Zhao M-L, Brosnan CF, Lee SC: Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1b and IL-1 receptor antagonist. J Immunol 1996, 157:3569-3576.
• [38]Martin M, Rehani K, Jope RS, Michalek SM: Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005, 6:777-784.
• [39]Luyendyk JP, Schabbauer GA, Tencati M, Holscher T, Pawlinski R, Mackman N: Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages. J Immunol 2008, 180:4218-4226.
• [40]Beaulieu JM, Gainetdinov RR, Caron MG: Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 2009, 49:327-347.
• [41]Liu JS, Amaral TD, Brosnan CF, Lee SC: IFNs are critical regulators of IL-1 receptor antagonist and IL-1 expression in human microglia. J Immunol 1998, 161:1989-1996.
• [42]McManus CM, Liu JS, Hahn MT, Hua LL, Brosnan CF, Berman JW, Lee SC: Differential induction of chemokines in human microglia by type I and II interferons. Glia 2000, 29:273-280.
• [43]Rani MR, Shrock J, Appachi S, Rudick RA, Williams BR, Ransohoff RM: Novel interferon-beta-induced gene expression in peripheral blood cells. J Leukoc Biol 2007, 82:1353-1360.
• [44]Gunzl P, Bauer K, Hainzl E, Matt U, Dillinger B, Mahr B, Knapp S, Binder BR, Schabbauer G: Anti-inflammatory properties of the PI3K pathway are mediated by IL-10/DUSP regulation. J Leukoc Biol 2010, 88:1259-1269.
• [45]Androulidaki A, Iliopoulos D, Arranz A, Doxaki C, Schworer S, Zacharioudaki V, Margioris AN, Tsichlis PN, Tsatsanis C: The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009, 31:220-231.
• [46]O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D: MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 2007, 104:1604-1609.
• [47]Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD: MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008, 9:839-845.
• [48]Sarkar SN, Peters KL, Elco CP, Sakamoto S, Pal S, Sen GC: Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling. Nat Struct Mol Biol 2004, 11:1060-1067.
• [49]Laird MH, Rhee SH, Perkins DJ, Medvedev AE, Piao W, Fenton MJ, Vogel SN: TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J Leukoc Biol 2009, 85:966-977.
• [50]Kim MO, Si Q, Zhou JN, Pestell RG, Brosnan CF, Locker J, Lee SC: Interferon-beta activates multiple signaling cascades in primary human microglia. J Neurochem 2002, 81:1361-1371.
• [51]Zhao ML, Kim MO, Morgello S, Lee SC: Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis. J Neuroimmunol 2001, 115:182-191.
• [52]Lee SC, Dickson DW, Brosnan CF: Interleukin-1, nitric oxide and reactive astrocytes. Brain, Behavior, and Immunity 1995, 9:345-354.
• [53]Simi A, Tsakiri N, Wang P, Rothwell NJ: Interleukin-1 and inflammatory neurodegeneration. Biochem Soc Trans 2007, 35:1122-1126.
• [54]Thornton P, Pinteaux E, Gibson RM, Allan SM, Rothwell NJ: Interleukin-1-induced neurotoxicity is mediated by glia and requires caspase activation and free radical release. J Neurochem 2006, 98:258-266.
• [55]Annunziato F, Romagnani S: Do studies in humans better depict Th17 cells? Blood 2009, 114:2213-2219.
• [56]Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L, Watowich SS, Jetten AM, Tian Q, Dong C: Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009, 30:576-587.
• [57]Lyakh L, Trinchieri G, Provezza L, Carra G, Gerosa F: Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev 2008, 226:112-131.
• [58]Aksentijevich I, Masters SL, Ferguson PJ, et al.: An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009, 360:2426-2437.
• [59]Dinarello CA: Interleukin-1beta and the autoinflammatory diseases. N Engl J Med 2009, 360:2467-2470.
• [60]Reddy S, Jia S, Geoffrey R, Lorier R, Suchi M, Broeckel U, Hessner MJ, Verbsky J: An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009, 360:2438-2444.
• [61]Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, Gruaz L, Chofflon M, Zamvil SS, Lalive PH: Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci USA 2009, 106:4355-4359.